242 related articles for article (PubMed ID: 30446464)
1. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
[TBL] [Abstract][Full Text] [Related]
2. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
[TBL] [Abstract][Full Text] [Related]
4. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M
Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Basch E; Loblaw DA; Oliver TK; Carducci M; Chen RC; Frame JN; Garrels K; Hotte S; Kattan MW; Raghavan D; Saad F; Taplin ME; Walker-Dilks C; Williams J; Winquist E; Bennett CL; Wootton T; Rumble RB; Dusetzina SB; Virgo KS
J Clin Oncol; 2014 Oct; 32(30):3436-48. PubMed ID: 25199761
[TBL] [Abstract][Full Text] [Related]
6. Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.
Martin SK; Pu H; Penticuff JC; Cao Z; Horbinski C; Kyprianou N
Cancer Res; 2016 Feb; 76(4):912-26. PubMed ID: 26645563
[TBL] [Abstract][Full Text] [Related]
7. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
González Del Alba A; Méndez-Vidal MJ; Vazquez S; Castro E; Climent MA; Gallardo E; Gonzalez-Billalabeitia E; Lorente D; Maroto JP; Arranz JA
Clin Transl Oncol; 2021 May; 23(5):969-979. PubMed ID: 33625671
[TBL] [Abstract][Full Text] [Related]
8. Castration-resistant prostate cancer: systemic therapy in 2012.
Maluf FC; Smaletz O; Herchenhorn D
Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
[TBL] [Abstract][Full Text] [Related]
9. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
Schweizer MT; Antonarakis ES; Wang H; Ajiboye AS; Spitz A; Cao H; Luo J; Haffner MC; Yegnasubramanian S; Carducci MA; Eisenberger MA; Isaacs JT; Denmeade SR
Sci Transl Med; 2015 Jan; 7(269):269ra2. PubMed ID: 25568070
[TBL] [Abstract][Full Text] [Related]
10. Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.
Mout L; de Wit R; Stuurman D; Verhoef E; Mathijssen R; de Ridder C; Lolkema M; van Weerden W
EBioMedicine; 2018 Jan; 27():182-186. PubMed ID: 29276148
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
Fujiwara S; Kosaka T; Nishimoto Y; Kamisawa K; Watanabe K; Baba Y; Takeda T; Matsumoto K; Oya M
Prostate; 2024 Jan; 84(1):25-31. PubMed ID: 37661578
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing treatment of veterans with advanced prostate cancer.
Caram MEV; Burns J; Kumbier K; Sparks JB; Tsao PA; Chapman CH; Bauman J; Hollenbeck BK; Shahinian VB; Skolarus TA
Cancer; 2021 Jul; 127(13):2311-2318. PubMed ID: 33764537
[TBL] [Abstract][Full Text] [Related]
13. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy.
Yoshida T; Kawai T; Hagiwara K; Yanagida K; Noda M; Tokura Y; Yoshimura I; Kaneko T; Nakagawa T
Jpn J Clin Oncol; 2024 Apr; 54(4):498-503. PubMed ID: 38251778
[TBL] [Abstract][Full Text] [Related]
14. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234
[TBL] [Abstract][Full Text] [Related]
15. Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.
Irelli A; Bruera G; Cannita K; Palluzzi E; Gravina GL; Festuccia C; Ficorella C; Ricevuto E
Biomed Res Int; 2014; 2014():909623. PubMed ID: 24971356
[TBL] [Abstract][Full Text] [Related]
16. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
[TBL] [Abstract][Full Text] [Related]
17. Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.
Conteduca V; Scarpi E; Salvi S; Casadio V; Lolli C; Gurioli G; Schepisi G; Wetterskog D; Farolfi A; Menna C; De Lisi D; Burgio SL; Beltran H; Attard G; De Giorgi U
Sci Rep; 2018 Oct; 8(1):15442. PubMed ID: 30337589
[TBL] [Abstract][Full Text] [Related]
18. Solid cancer: the new tumour spread endpoint opens novel opportunities.
Fernandes M; Rosel D; Brábek J
Br J Cancer; 2019 Oct; 121(7):513-514. PubMed ID: 31427682
[TBL] [Abstract][Full Text] [Related]
19. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
[TBL] [Abstract][Full Text] [Related]
20. Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Vaishampayan UN
Curr Opin Oncol; 2015 May; 27(3):201-8. PubMed ID: 25811344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
